GSK and Valeant's retigabine fails Phase II postherpetic pain study
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline/Valeant Pharmaceuticals' potassium channel opener retigabine has failed to meet the primary endpoint of a Phase IIa proof-of-concept trial for the treatment of pain associated with postherpetic neuralgia.